Compare Stocks → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CINGNASDAQ:LIPONASDAQ:NEXINYSE:OGEN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$0.80+1.3%$0.98$0.70▼$21.80$4.85M-0.87271,036 shs16,553 shsLIPOLipella Pharmaceuticals$0.75-1.3%$0.73$0.64▼$2.71$5.80M0.7745,256 shs56,290 shsNEXINexImmune$3.34-2.9%$4.31$1.25▼$28.69$4.57M2.031.45 million shs5,335 shsOGENOragenics$2.33+42.1%$1.32$1.00▼$7.74$10.44M0.494,072 shs522,449 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+1.51%+5.37%-8.25%-30.87%-95.78%LIPOLipella Pharmaceuticals-1.50%+2.60%+0.27%-24.90%-60.89%NEXINexImmune-1.88%-7.33%+5.90%-57.12%-55.52%OGENOragenics+42.94%+28.02%+115.74%-62.04%-21.02%I’m afraid WWIII is a very real possibility (Ad)As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film.Take a look.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCINGCingulate2.9358 of 5 stars3.25.00.00.01.94.20.0LIPOLipella Pharmaceuticals3.3868 of 5 stars3.55.00.00.01.75.00.0NEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate2.33Hold$8.00897.63% UpsideLIPOLipella Pharmaceuticals3.00Buy$2.00166.31% UpsideNEXINexImmuneN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/ACurrent Analyst RatingsLatest OGEN, NEXI, CING, and LIPO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024LIPOLipella PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$2.00(Data available from 5/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$0.53 per shareN/ALIPOLipella Pharmaceuticals$449.62K12.70N/AN/A$0.34 per share2.21NEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/AOGENOragenics$40K260.96N/AN/A$0.61 per share3.82Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$23.53MN/A0.00∞N/AN/AN/A-448.18%8/12/2024 (Estimated)LIPOLipella Pharmaceuticals-$4.62MN/A0.00∞N/A-992.04%-171.66%-145.43%5/20/2024 (Estimated)NEXINexImmune-$32.34M-$30.89N/A∞N/AN/A-247.17%-167.39%5/20/2024 (Estimated)OGENOragenics-$20.66M-$8.54N/A∞N/AN/A-500.58%-284.99%N/ALatest OGEN, NEXI, CING, and LIPO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/16/2024Q4 2023NEXINexImmuneN/A-$4.99-$4.99-$4.99N/AN/A3/29/2024Q4 2023OGENOragenicsN/A-$5.48-$5.48-$5.48N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulateN/A1.211.21LIPOLipella PharmaceuticalsN/A5.455.45NEXINexImmuneN/A1.061.06OGENOragenicsN/A2.152.15OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%LIPOLipella Pharmaceuticals74.31%NEXINexImmune9.85%OGENOragenics18.71%Insider OwnershipCompanyInsider OwnershipCINGCingulate38.43%LIPOLipella Pharmaceuticals39.58%NEXINexImmune19.40%OGENOragenics24.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate136.05 million3.72 millionNot OptionableLIPOLipella Pharmaceuticals57.61 million4.60 millionNot OptionableNEXINexImmune221.37 million1.11 millionNot OptionableOGENOragenics54.48 million3.38 millionN/AOGEN, NEXI, CING, and LIPO HeadlinesRecent News About These CompaniesMay 18 at 3:40 AM | americanbankingnews.comOragenics (NYSE:OGEN) Research Coverage Started at StockNews.comMay 17 at 8:00 AM | globenewswire.comOragenics, Inc. to Host Webinar Panel on Neurotrauma MedicineMay 16 at 12:42 PM | msn.comOragenics climbs 9% amid Phase 2 study, business updatesMay 16 at 9:58 AM | finance.yahoo.comOragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion TrialMay 16 at 12:06 AM | investorplace.comOGEN Stock Earnings: Oragenics Reported Results for Q1 2024May 11, 2024 | finance.yahoo.comOragenics, Inc. (OGEN)May 7, 2024 | msn.comOragenics partners with Avance Clinical for Phase 2 concussion studyMay 7, 2024 | finance.yahoo.comOragenics Partners with Avance Clinical for Phase II Concussion Trial in AustraliaApril 27, 2024 | finance.yahoo.comOragenics, Inc. (OGEN) Stock Price, News, Quote & History - Yahoo FinanceApril 20, 2024 | finance.yahoo.comOdyssey Health, Inc. (ODYY)April 19, 2024 | businesswire.comOragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsApril 17, 2024 | money.usnews.comOragenics IncApril 16, 2024 | ca.finance.yahoo.comOragenics, Inc. (OGEN) Latest Stock News & Headlines - Yahoo FinanceApril 1, 2024 | finance.yahoo.comOragenics, Inc. Files 10K and Provides Company UpdateMarch 18, 2024 | markets.businessinsider.comOragenics Appoints Kelly As Chief Medical OfficerMarch 17, 2024 | finance.yahoo.com15 Highest Quality Probiotics For Gut HealthMarch 5, 2024 | businesswire.comOragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionMarch 1, 2024 | businesswire.comOragenics Announces Closing of Public OfferingMarch 1, 2024 | uk.investing.comOragenics announces public stock offeringFebruary 28, 2024 | investorplace.comWhy Is Oragenics (OGEN) Stock Down 45% Today?New MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesMU Nears Breakout as Analysts Continue to Pound the TableMay 8, 2024 7:11 AMView MU Nears Breakout as Analysts Continue to Pound the Table5 Aerospace & Defense Stocks Ready for LiftoffMay 1, 2024 8:41 AMView 5 Aerospace & Defense Stocks Ready for LiftoffPlug Power is Building the Future of Hydrogen Despite HeadwindsMay 10, 2024 7:17 AMView Plug Power is Building the Future of Hydrogen Despite HeadwindsDid the Rally in Coca-Cola Company Stock Just Fizzle Out?April 30, 2024 9:15 AMView Did the Rally in Coca-Cola Company Stock Just Fizzle Out?Will the Biotech Sector Shift From Lagger to Leader?May 10, 2024 7:24 AMView Will the Biotech Sector Shift From Lagger to Leader?All HeadlinesCompany DescriptionsCingulateNASDAQ:CINGCingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Lipella PharmaceuticalsNASDAQ:LIPOLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.NexImmuneNASDAQ:NEXINexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.OragenicsNYSE:OGENOragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.